In this video, Jeff Yu, MD, MS, highlighted the possible future directions of atopic dermatitis like further development of topical therapies, combination therapies and discussions of disease ...

In this video, Jeff Yu, MD, MS, highlighted research from the Revolutionizing Atopic Dermatitis, or RAD, meeting and said the disease has “leapt to the forefront” of dermatologic diseases with ...

While some topical herbal therapies may provide benefit for patients with AD, systemic herbal therapies do not provide significant benefit.

Findings from a recent phase 3b/4 study of upadacitinib support a treat-to-target strategy for dose escalation or reduction ...

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the most promising stocks according to Wall Street analysts. On June 26, ...

A recent study reveals that a novel postbiotic supplement, Pet Immune, significantly alleviates itching and enhances skin and ...

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.

Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” the “Company”) today announced that Institutional Shareholder Services Inc.

Apogee Therapeutics (NASDAQ:APGE) stock drops despite mid-stage trial success for APG777 in treating atopic dermatitis. Read ...

Researchers have found in a new systematic review and meta-analysis that higher levels of environmental pollutants and ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...